Phio Pharmaceuticals Corp.
(NASDAQ : PHIO)

( )
PHIO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.28%61.090.0%$918.14m
NVAXNovavax, Inc. 31.62%104.56102.0%$825.80m
AMGNAmgen, Inc. -1.21%253.151.3%$733.54m
REGNRegeneron Pharmaceuticals, Inc. 2.17%640.882.5%$687.80m
GILDGilead Sciences, Inc. -0.44%76.421.0%$676.56m
BIIBBiogen, Inc. -0.54%268.351.6%$573.84m
VRTXVertex Pharmaceuticals, Inc. 2.66%299.061.9%$522.97m
ILMNIllumina, Inc. -1.92%372.123.5%$297.26m
ALXNAlexion Pharmaceuticals, Inc. -0.98%112.462.0%$230.21m
BMRNBioMarin Pharmaceutical, Inc. 0.21%127.984.3%$212.65m
SGENSeattle Genetics, Inc. 3.34%176.146.1%$207.80m
SRNESorrento Therapeutics, Inc. 3.00%7.381.8%$195.17m
IMMUImmunomedics, Inc. 1.30%41.1611.0%$178.10m
SRPTSarepta Therapeutics, Inc. 0.25%163.8913.9%$167.23m
INCYIncyte Corp. 0.80%108.652.5%$166.01m

Company Profile

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.